Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03UAE
|
|||
Drug Name |
US9073931, E2
|
|||
Synonyms |
SCHEMBL15273082; CHEMBL3673669; LOFRRPNYSLDHRM-UHFFFAOYSA-N; BDBM168073; US9073931, E2; 2-(2-(1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)propan-2-ol
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H26F3N5O3S
|
|||
Canonical SMILES |
CC(C)C1C2=NC3=C(N2CCN1C4=NC=C(C(=N4)C(F)(F)F)C(C)(C)O)C=C(C=C3)S(=O)(=O)C
|
|||
InChI |
1S/C22H26F3N5O3S/c1-12(2)17-19-27-15-7-6-13(34(5,32)33)10-16(15)29(19)8-9-30(17)20-26-11-14(21(3,4)31)18(28-20)22(23,24)25/h6-7,10-12,17,31H,8-9H2,1-5H3
|
|||
InChIKey |
LOFRRPNYSLDHRM-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Inhibitor | [1] |
Target's Patent Info | Oxysterols receptor LXR-alpha (NR1H3) | Target's Patent Info | [1] | |
KEGG Pathway | PPAR signaling pathway | |||
Non-alcoholic fatty liver disease (NAFLD) | ||||
Hepatitis C | ||||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
Nuclear Receptors Meta-Pathway | ||||
PPAR Alpha Pathway | ||||
Liver X Receptor Pathway | ||||
Adipogenesis | ||||
SREBF and miR33 in cholesterol and lipid homeostasis | ||||
Nuclear Receptors |
References | Top | |||
---|---|---|---|---|
REF 1 | Liver X receptor modulators. US9073931. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.